HAMAM

Despite tremendous advances in modern imaging technology, both early detection and accurate diagnosis of breast cancer are still unresolved challenges. Today, a variety of imaging modalities and image-guided biopsy procedures exist to identify and characterize morphology and function of suspicious breast tissue. However, a clinically feasible solution for breast imaging, which is both highly sensitive and specific with respect to breast cancer, is still missing. As a consequence, unnecessary biopsies are taken and tumours frequently go undetected until a stage where therapy is costly or unsuccessful.

HAMAM (Highly accurate breast cancer diagnosis through integration of biological knowledge, novel imaging modalities, and modelling) project will tackle this challenge by providing a means to seamlessly integrate the available multi-modal images and the patient information on a single clinical workstation. Based on knowledge gained from a large multi-disciplinary database, populated within the scope of this project, suspicious breast tissue will be characterised and classified.

HAMAM will achieve this by:

  • Building the tools needed to integrate datasets / modalities into a single interface.
  • Providing pre processing / standardization tools that will allow for optimal comparison of disparate data
  • Building spatial correlation information datasets to allow for new similarity and multimodal tissue models. These will be key in the detection and diagnosis of breast cancer
  • Building in adaptability that allows for the integration of other sources of knowledge such as tumour models, genetic data, genotype, phenotype and standardised imaging.

The exact diagnosis of suspicious breast tissue is ambiguous in many cases. HAMAM will resolve this using the statistical knowledge extracted from the large case database. The clinical workstation will suggest additional image modalities that may be captured to optimally resolve these uncertainties. The workstation thus guides the clinician in establishing a patient specific optimal diagnosis. This ultimately leads to a more specific and individual diagnosis.

For further information, please visit:
http://www.hamam-project.eu

Project co-ordinator:
EIBIR gemeinnuetzige GmbH zur Foerderung der. Erforschung der biomedizinischen Bildgebung

Partners:

  • Boca Raton Community Hospital Inc (USA)
  • MeVis Research GmbH (Germany)
  • MeVis Medical Solutions AG (Germany)
  • University College London (United Kingdom)
  • Radboud Universiteit Nijmegen - Stichting Katholieke Universiteit (Netherlands)
  • Charité - Universitätsmedizin Berlin (Germany)
  • The University of Dundee (United Kingdom)
  • Eidgenössische Technische Hochschule Zürich (Switzerland)

Timetable: from 09/2008 - to 08/2011

Total cost: € 4.250.000

EC funding: € 3.100.000

Programme Acronym: FP7-ICT

Subprogramme Area: Virtual physiological human

Contract type: Collaborative project (generic)


Related news article:

Most Popular Now

Contact Tracing Apps Unlikely to Contain…

Contract tracing apps used to reduce the spread of COVID-19 are unlikely to be effective without proper uptake and support from concurrent control measures, finds a new study by UCL...

Philips Launches New Innovations to Help…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today presented new approaches to health and healthcare, and the shift to health-at-home, at its virtual consumer health...

Internet Searches for Anxiety Attacks Ta…

Many health experts are concerned that the COVID-19 pandemic could be having widespread effects on people's mental health, but assessing these concerns is difficult without data. "Traditional public health surveillance lacks...

Orion Health Secures Place on Emerging T…

Remote Patient Monitoring solution included on Crown Commercial Services Spark: Technology Innovation Marketplace. Healthcare organisations now have a simple route to procure personalised monitoring for people living with chronic conditions to...

Scientists Develop Low-Cost Chip to Dete…

Robust and widespread antibody testing has emerged as a key strategy in the fight against SARS-CoV-2, the virus responsible for the COVID-19 pandemic. However current testing methods are too inaccurate...

Newly Merged CCG Expands Tech Support to…

Norfolk and Waveney Clinical Commissioning Group to support prescribers to improve the quality and safety of prescribing through deploying prescribing decision technology FDB OptimiseRx. A newly merged clinical commissioning group...

Anonymized Cell Phone Location Data can …

In March 2020, federal officials declared the COVID-19 outbreak a national emergency. Around the same time, most states implemented stay-at-home advisories - to different degrees and at different times. Publicly...

Designed Antiviral Proteins Inhibit SARS…

Computer-designed small proteins have now been shown to protect lab-grown human cells from SARS-CoV-2, the coronavirus that causes COVID-19. The findings are reported today in Science. In the experiments, the lead...

Telehealth Scales Up During the Pandemic…

Hailed for its ability to erase distance between health care providers in cities and patients in rural areas, telehealth has ironically enabled medical care to continue in a time when...

Fitbit Receives Regulatory Clearance in …

Fitbit (NYSE:FIT) has received 510(k) clearance from the U.S. Food and Drug Administration (FDA), as well as Conformité Européenne (CE) marking in the European Union, for its electrocardiogram (ECG) app...

Don't Fall for the 'Next Best Action' Tr…

15 September, 2020. London, UK. OKRA has announced a new, free webinar called 'Why Next Best Action is not enough', a panel will discuss the urgent need to move beyond the...

Cerner Chosen to Support Population Heal…

Cerner Corporation is pleased to announce a new relationship with Hampshire and Isle of Wight (HIOW) health and care system to enable their population health management journey to transform the...